Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Piper Sandler from $12.00 to $4.00. They now have an "overweight" rating on the stock.
Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic [Yahoo! Finance]
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Chardan Capital from $17.00 to $11.00. They now have a "buy" rating on the stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at HC Wainwright from $9.00 to $5.00. They now have a "buy" rating on the stock.